Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Pharmaceuticals Stock Is Sinking Today

By Keith Speights – Jun 30, 2020 at 10:24AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's "positive" results from an early-stage study weren't positive enough for investors.

What happened

Shares of Inovio Pharmaceuticals (INO 3.19%) were sinking 11.8% lower as of 11:01 a.m. EDT on Tuesday. The decline came after the biotech announced interim results from an early-stage clinical study of COVID-19 vaccine candidate INO-4800. Inovio referred to the data as "positive." However, industry observers didn't think the company disclosed enough information to draw any meaningful conclusions about the efficacy of the experimental vaccine.

So what

Inovio stated that 94% of the 40 participants in its early-stage study "demonstrated overall immune responses" six weeks after receiving two doses of INO-4800. The problem, though, is that the biotech didn't provide any details about how many patients produced neutralizing antibodies. These antibodies prevent infection by the novel coronavirus.

Gloved hands holding COVID-19 vaccine syringe

Image source: Getty Images.

It even seemed that Inovio could be attempting to downplay the importance of neutralizing antibodies. In the company's press release announcing the interim phase 1 results for INO-4800, Inovio referenced two studies published earlier this year that found between 33% and 40% of individuals who recovered from COVID-19 had low levels of neutralizing antibodies.

Investors appear to be concerned that INO-4800 might not be as effective as other COVID-19 vaccines in development. Moderna, for example, disclosed information about the number of patients producing binding antibodies and neutralizing antibodies in its interim phase 1 results.

Safety didn't appear to be a serious concern for INO-4800, though. Inovio reported that the experimental vaccine was "generally safe and well-tolerated in all participants." There were 10 adverse events reported. Each was grade 1 in severity, the lowest severity level. Most were related to injection site redness. Inovio said that there were no serious adverse events reported.

Now what

Inovio hopes to begin a phase 2/3 clinical study evaluating the efficacy of INO-4800 this summer assuming it gets a green light from the FDA. INO-4800 has also been selected to be part of a preclinical trial funded by Operation Warp Speed, the U.S. government's program to rapidly develop a COVID-19 vaccine. The biotech stock could be highly volatile, however, until investors are more comfortable about the efficacy of Inovio's coronavirus vaccine candidate.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.78 (3.19%) $0.06
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$121.81 (3.01%) $3.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.